Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients-Reference-Cited by-同舟云学术

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

Published:2023-03-22 Issue:6 Volume:91 Page:447-456
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Groenland Stefanie L.^ORCID,Janssen J. M.,Nijenhuis C. M.,de Vries N.,Rosing H.,Wilgenhof S.,van Thienen J. V.,Haanen J. B. A. G.,Blank C. U.,Beijnen J. H.,Huitema A. D. R.,Steeghs N.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-023-04517-8.pdf

Reference29 articles.

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

2. The Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161:1681–1696

3. Rozeman EA, Dekker TJA, Haanen JBAG, Blank CU (2018) Advanced melanoma: current treatment options, biomarkers, and future perspectives. Am J Clin Dermatol 19:303–317

4. Ouellet D, Gibiansky E, Leonowens C, O’Hagan A, Haney P, Switzky J et al (2014) Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites. J Clin Pharmacol 54:696–706

5. Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D et al (2016) Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol 77:807–817

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study;Cancers;2024-06-11

2. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer;Thyroid®;2023-11-01

3. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16